Moonlake Immunotherapeutics (MLTX)

$17.36 +0.84 (5.08%)
Market Cap 1.25B
Revenue (ttm) 0.00
Net Income (ttm) -227.32M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.24
Volume 1,687,000
Avg Vol 1,236,100
Day's Range N/A - N/A
Shares Out 71.73M
Stochastic %K 49%
Beta 1.19
Analysts Strong Sell
Price Target $29.83

Company Profile

MoonLake Immunotherapeutics, a clinical-stage biotechnology company, focuses on developing therapies for inflammatory skin and joint diseases. It develops Sonelokimab, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody for the treatment of inflammatory diseases in dermatology and rheumatology, as well as for hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, palmoplantar pustulosis, and psoriasis. The company was founded in 2021 and is headquartered in Zug, Switzerla...

Industry: Biotechnology
Sector: Healthcare
Phone: 41 415108022
Address:
Dorfstrasse 29, Zug, Switzerland
Rockybhai7239
Rockybhai7239 Apr. 5 at 12:42 AM
$MLTX
0 · Reply
GrumpyCrow
GrumpyCrow Apr. 5 at 12:22 AM
$MLTX so they are gonna short the shit out of this to lower the sp as much as possible to make an offer seem like the premium over the share price offered is a good deal?
0 · Reply
Modern_portholio_theory
Modern_portholio_theory Apr. 4 at 11:49 PM
$MLTX a lot of reading to catch up on here; indications of various pharma jets at zurich in similar time frame to bvf sale price action rising post bvf sale rather than dropping available shares which can be borrowed rise after bvf sale rather than dropping speculation on a form 13 in 5 or 10 days post bvf sale if >5% purchase by big pharma, rather then 45days post qtr end bear hug letter speculation ? had not heard this term before trump new tariffs on pharma outside of usa time being ripe for a good buy prior to 52 week data i think i may have covered most… and here i am still focused on june for 52 week data—
0 · Reply
Obidagreat
Obidagreat Apr. 4 at 11:01 PM
$MLTX
0 · Reply
Lisajane
Lisajane Apr. 4 at 10:17 PM
$MLTX If a great white shark has bared its teeth, I don’t think dinner will last until August!
0 · Reply
Bigpapa46
Bigpapa46 Apr. 4 at 10:17 PM
$MLTX I dont see them taking anything less than 7 billion especially if the 52 week data proves best in class. I think $77 a share is a little to low and gives them an evaluation of a little over 5.5 billion. 7 billion=$97 a share 8 billion=$111 9 billion= $125 10 billion= $139
4 · Reply
Jkm11
Jkm11 Apr. 4 at 9:22 PM
$MLTX taking a break at the beach today. Okaloosa Island, near Destin.
2 · Reply
Shaybe16569
Shaybe16569 Apr. 4 at 9:03 PM
$MLTX
0 · Reply
LouKojak
LouKojak Apr. 4 at 8:50 PM
$MLTX $77.01
0 · Reply
rrobers6
rrobers6 Apr. 4 at 8:31 PM
$MLTX Just confirming Lilly is a medicine company. That's all
1 · Reply
Latest News on MLTX
MoonLake announces Week 40 Results from its Phase 3 Clinical Trials of Sonelokimab in Hidradenitis Suppurativa at the 2026 AAD Annual Meeting

Mar 28, 2026, 3:00 PM EDT - 7 days ago

MoonLake announces Week 40 Results from its Phase 3 Clinical Trials of Sonelokimab in Hidradenitis Suppurativa at the 2026 AAD Annual Meeting

MoonLake: Downgrade To Buy As Sonelokimab Still Has A BLA Shot On Goal

Feb 24, 2026, 1:50 PM EST - 5 weeks ago

MoonLake: Downgrade To Buy As Sonelokimab Still Has A BLA Shot On Goal

MoonLake Immunotherapeutics (MLTX) Analyst/Investor Day Transcript

Feb 23, 2026, 3:24 PM EST - 5 weeks ago

MoonLake Immunotherapeutics (MLTX) Analyst/Investor Day Transcript

MoonLake Immunotherapeutics Data Shows Phase 2 Success For Chronic Back Pain

Feb 23, 2026, 9:10 AM EST - 5 weeks ago

MoonLake Immunotherapeutics Data Shows Phase 2 Success For Chronic Back Pain

ImageneBio Appoints Immunology Drug Development Veteran Dr. Ben Porter-Brown as Chief Medical Officer

Feb 10, 2026, 7:00 AM EST - 7 weeks ago

ImageneBio Appoints Immunology Drug Development Veteran Dr. Ben Porter-Brown as Chief Medical Officer

IMA

MoonLake Announces FDA Fast Track Designation for Sonelokimab Palmoplantar Pustulosis (PPP) and Provides Details on Upcoming Investor Day

Feb 2, 2026, 8:00 AM EST - 2 months ago

MoonLake Announces FDA Fast Track Designation for Sonelokimab Palmoplantar Pustulosis (PPP) and Provides Details on Upcoming Investor Day

Helix Acquisition Corp. III Announces Closing of $172.5 Million Initial Public Offering, Including the Full Exercise of the Underwriter's Option to Purchase Additional Shares

Jan 27, 2026, 7:30 AM EST - 2 months ago

Helix Acquisition Corp. III Announces Closing of $172.5 Million Initial Public Offering, Including the Full Exercise of the Underwriter's Option to Purchase Additional Shares

Helix Acquisition Corp. III Announces Pricing of Upsized $150 Million Initial Public Offering

Jan 23, 2026, 7:30 AM EST - 2 months ago

Helix Acquisition Corp. III Announces Pricing of Upsized $150 Million Initial Public Offering

MoonLake: Positive FDA Meeting Spurs Momentum Ahead Of BLA Submission

Jan 9, 2026, 8:15 AM EST - 3 months ago

MoonLake: Positive FDA Meeting Spurs Momentum Ahead Of BLA Submission

MoonLake Says FDA May Allow Skin Drug Filing Without New Trials, Stock Soars

Jan 8, 2026, 2:06 PM EST - 3 months ago

MoonLake Says FDA May Allow Skin Drug Filing Without New Trials, Stock Soars

MOONLAKE DECEMBER 15th DEADLINE: Bragar Eagel & Squire, P.C. Urgently Reminds MoonLake Immunotherapeutics Investors to Contact the Firm

Dec 15, 2025, 10:46 AM EST - 3 months ago

MOONLAKE DECEMBER 15th DEADLINE: Bragar Eagel & Squire, P.C. Urgently Reminds MoonLake Immunotherapeutics Investors to Contact the Firm

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of MoonLake Immunotherapeutics

Dec 11, 2025, 10:08 AM EST - 4 months ago

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of MoonLake Immunotherapeutics

DEADLINE NEXT WEEK: Berger Montague Advises MoonLake Immunotherapeutics (NASDAQ: MLTX) Investors to Contact the Firm Before December 15, 2025

Dec 11, 2025, 8:54 AM EST - 4 months ago

DEADLINE NEXT WEEK: Berger Montague Advises MoonLake Immunotherapeutics (NASDAQ: MLTX) Investors to Contact the Firm Before December 15, 2025

MLTX INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of MoonLake Immunotherapeutics

Dec 8, 2025, 1:23 PM EST - 4 months ago

MLTX INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of MoonLake Immunotherapeutics

Stock Picks From Seeking Alpha's November 2025 New Analysts

Dec 8, 2025, 9:00 AM EST - 4 months ago

Stock Picks From Seeking Alpha's November 2025 New Analysts

ABEV CEG CEPU EAT GLXY GT KOF

MoonLake Immunotherapeutics (MLTX) Investors are Encouraged to Act before the Upcoming December 15 Securities Fraud Deadline – Contact BFA Law if You Lost Money

Dec 5, 2025, 8:18 AM EST - 4 months ago

MoonLake Immunotherapeutics (MLTX) Investors are Encouraged to Act before the Upcoming December 15 Securities Fraud Deadline – Contact BFA Law if You Lost Money

MoonLake's (MLTX) SLK Efficacy Claims Under Scrutiny After 90% Plunge; Focus on Nanobody vs. BIMZELX Superiority- Hagens Berman

Dec 5, 2025, 8:06 AM EST - 4 months ago

MoonLake's (MLTX) SLK Efficacy Claims Under Scrutiny After 90% Plunge; Focus on Nanobody vs. BIMZELX Superiority- Hagens Berman

MLTX Lawsuit: Hagens Berman Scrutinizing MoonLake's SLK Efficacy Claims After 90% Plunge; Focus on Nanobody vs. BIMZELX Superiority

Dec 4, 2025, 3:01 PM EST - 4 months ago

MLTX Lawsuit: Hagens Berman Scrutinizing MoonLake's SLK Efficacy Claims After 90% Plunge; Focus on Nanobody vs. BIMZELX Superiority

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of December 15, 2025 in MoonLake Lawsuit - MLTX

Dec 4, 2025, 9:00 AM EST - 4 months ago

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of December 15, 2025 in MoonLake Lawsuit - MLTX

MLTX NEWS: MoonLake Immunotherapeutics Sued for Securities Fraud after Stock Plummets 90% -- Investors Notified to Contact BFA Law by December 15 Deadline

Dec 3, 2025, 7:46 AM EST - 4 months ago

MLTX NEWS: MoonLake Immunotherapeutics Sued for Securities Fraud after Stock Plummets 90% -- Investors Notified to Contact BFA Law by December 15 Deadline

Bragar Eagel & Squire, P.C. Urges Investors of Cepton, and MoonLake to Inquire About Their Rights Before Upcoming Deadlines

Dec 2, 2025, 5:29 PM EST - 4 months ago

Bragar Eagel & Squire, P.C. Urges Investors of Cepton, and MoonLake to Inquire About Their Rights Before Upcoming Deadlines

CPTN

UPCOMING DEADLINE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of MoonLake Immunotherapeutics

Dec 1, 2025, 5:52 PM EST - 4 months ago

UPCOMING DEADLINE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of MoonLake Immunotherapeutics

MLTX SHAREHOLDERS: MoonLake Immunotherapeutics Investors with Losses may have been Misled by the Company and are Urged to Contact BFA Law by December 15

Dec 1, 2025, 3:18 PM EST - 4 months ago

MLTX SHAREHOLDERS: MoonLake Immunotherapeutics Investors with Losses may have been Misled by the Company and are Urged to Contact BFA Law by December 15

Voya MidCap Opportunities Strategy Q3 2025 Portfolio Review

Dec 1, 2025, 12:26 PM EST - 4 months ago

Voya MidCap Opportunities Strategy Q3 2025 Portfolio Review

APP FIX KTOS TW VRSK

MLTX LAWSUIT: BFA Law Reminds MoonLake Immunotherapeutics Investors the Company has been Sued for Securities Fraud and to Contact BFA Law by December 15 Deadline

Nov 30, 2025, 7:45 AM EST - 4 months ago

MLTX LAWSUIT: BFA Law Reminds MoonLake Immunotherapeutics Investors the Company has been Sued for Securities Fraud and to Contact BFA Law by December 15 Deadline

MoonLake Immunotherapeutics' (MLTX) Stock Crashes 90%, Triggers Lawsuit After Reported Phase 3 Trial Data for Sole Drug Candidate -- Hagens Berman

Nov 28, 2025, 5:50 PM EST - 4 months ago

MoonLake Immunotherapeutics' (MLTX) Stock Crashes 90%, Triggers Lawsuit After Reported Phase 3 Trial Data for Sole Drug Candidate -- Hagens Berman

MoonLake Immunotherapeutics' (MLTX) Reported Phase 3 Trial Data for Sole Drug Candidate, 90% Stock Crash Triggers Investor Suit -- Hagens Berman

Nov 27, 2025, 2:15 PM EST - 4 months ago

MoonLake Immunotherapeutics' (MLTX) Reported Phase 3 Trial Data for Sole Drug Candidate, 90% Stock Crash Triggers Investor Suit -- Hagens Berman

MOONLAKE NOTICE: MoonLake Immunotherapeutics (MLTX) Faces Securities Fraud Allegations after Stock Drops 90%, Investors Urged to Contact BFA Law

Nov 24, 2025, 6:08 AM EST - 4 months ago

MOONLAKE NOTICE: MoonLake Immunotherapeutics (MLTX) Faces Securities Fraud Allegations after Stock Drops 90%, Investors Urged to Contact BFA Law

MoonLake: Ignore The Panic, Catch The Upside

Nov 18, 2025, 12:33 AM EST - 4 months ago

MoonLake: Ignore The Panic, Catch The Upside

MOONLAKE INVESTORS: MoonLake Immunotherapeutics (MLTX) has been Sued for Securities Fraud, Investors are Urged to Contact BFA Law

Nov 14, 2025, 6:08 AM EST - 5 months ago

MOONLAKE INVESTORS: MoonLake Immunotherapeutics (MLTX) has been Sued for Securities Fraud, Investors are Urged to Contact BFA Law

MOONLAKE IMMUNOTHERAPEUTICS (NASDAQ: MLTX) DEADLINE ALERT Bernstein Liebhard LLP Reminds MoonLake Immunotherapeutics Investors of Upcoming Deadline

Nov 10, 2025, 8:15 AM EST - 5 months ago

MOONLAKE IMMUNOTHERAPEUTICS (NASDAQ: MLTX) DEADLINE ALERT Bernstein Liebhard LLP Reminds MoonLake Immunotherapeutics Investors of Upcoming Deadline

MLTX STOCK NOTICE: MoonLake Immunotherapeutics Investors with Losses may have been Misled by the Company and are Urged to Contact BFA Law by December 15 Deadline

Nov 10, 2025, 6:06 AM EST - 5 months ago

MLTX STOCK NOTICE: MoonLake Immunotherapeutics Investors with Losses may have been Misled by the Company and are Urged to Contact BFA Law by December 15 Deadline

MoonLake Immunotherapeutics Announces Pricing of $75 Million Underwritten Offering

Nov 5, 2025, 7:11 AM EST - 5 months ago

MoonLake Immunotherapeutics Announces Pricing of $75 Million Underwritten Offering

MoonLake Immunotherapeutics Reports Third Quarter 2025 Financial Results and Announces New Data from Clinical Trials of its Nanobody® Sonelokimab

Nov 5, 2025, 7:00 AM EST - 5 months ago

MoonLake Immunotherapeutics Reports Third Quarter 2025 Financial Results and Announces New Data from Clinical Trials of its Nanobody® Sonelokimab

Rockybhai7239
Rockybhai7239 Apr. 5 at 12:42 AM
$MLTX
0 · Reply
GrumpyCrow
GrumpyCrow Apr. 5 at 12:22 AM
$MLTX so they are gonna short the shit out of this to lower the sp as much as possible to make an offer seem like the premium over the share price offered is a good deal?
0 · Reply
Modern_portholio_theory
Modern_portholio_theory Apr. 4 at 11:49 PM
$MLTX a lot of reading to catch up on here; indications of various pharma jets at zurich in similar time frame to bvf sale price action rising post bvf sale rather than dropping available shares which can be borrowed rise after bvf sale rather than dropping speculation on a form 13 in 5 or 10 days post bvf sale if >5% purchase by big pharma, rather then 45days post qtr end bear hug letter speculation ? had not heard this term before trump new tariffs on pharma outside of usa time being ripe for a good buy prior to 52 week data i think i may have covered most… and here i am still focused on june for 52 week data—
0 · Reply
Obidagreat
Obidagreat Apr. 4 at 11:01 PM
$MLTX
0 · Reply
Lisajane
Lisajane Apr. 4 at 10:17 PM
$MLTX If a great white shark has bared its teeth, I don’t think dinner will last until August!
0 · Reply
Bigpapa46
Bigpapa46 Apr. 4 at 10:17 PM
$MLTX I dont see them taking anything less than 7 billion especially if the 52 week data proves best in class. I think $77 a share is a little to low and gives them an evaluation of a little over 5.5 billion. 7 billion=$97 a share 8 billion=$111 9 billion= $125 10 billion= $139
4 · Reply
Jkm11
Jkm11 Apr. 4 at 9:22 PM
$MLTX taking a break at the beach today. Okaloosa Island, near Destin.
2 · Reply
Shaybe16569
Shaybe16569 Apr. 4 at 9:03 PM
$MLTX
0 · Reply
LouKojak
LouKojak Apr. 4 at 8:50 PM
$MLTX $77.01
0 · Reply
rrobers6
rrobers6 Apr. 4 at 8:31 PM
$MLTX Just confirming Lilly is a medicine company. That's all
1 · Reply
cranberry1
cranberry1 Apr. 4 at 7:55 PM
$MLTX 77!
1 · Reply
Creisi
Creisi Apr. 4 at 5:46 PM
$MLTX One of the things I always say is clinical biopharma companies should focus developing their pipelines to be as appealing as possible for the Big Pharma Great White Sharks . Those that do are who I want to invest in. Great White's love simple, high volume great tasting meals that don't have a ton of different tastes in the same bite.. their pallets are NOT built for complex tastes. THEY'd rather one big juicy seal over 25 little mackerel. A 'bolt on' product like SLK is a perfect Great white meal and is the perfect bait whether management at MLTX intended to make it one or not; it simply is.
0 · Reply
Creisi
Creisi Apr. 4 at 5:19 PM
$MLTX Your definition is 100%. And yes they are actually common practice for Big Pharma. This is especially true after they isolate a target asset, like SLK, and have been rejected by the board in a non tendered offer. There are 3 companies highly interested in SLK; it's MERCK, LILLY and NOVARTIS. I believe one of them said; "we're not fuckin' around with these guys at MLTX anymore, move on them." " Let's talk to the key shareholder, make a deal, get a seat at the table, and then feast." "They can agree the easy way, or we'll do it the hard way." It's how it's done.
2 · Reply
Creisi
Creisi Apr. 4 at 4:53 PM
$MLTX "Merck reported a couple of weeks ago that they have reallocated $15 billion for upcoming M&A." TO THE SHORT DIMWITS, I AM NOT SAYING THEY'RE PAYING $15 BILLION FOR MLTX. I'M SAYING EXACTLY WHAT I TYPED. Essentially, Merck is on the prowl.
2 · Reply
Obidagreat
Obidagreat Apr. 4 at 4:49 PM
$MLTX
0 · Reply
cranberry1
cranberry1 Apr. 4 at 4:45 PM
$MLTX 77!
0 · Reply
cranberry1
cranberry1 Apr. 4 at 4:44 PM
$MLTX I've revised my target $77
0 · Reply
cranberry1
cranberry1 Apr. 4 at 4:44 PM
$MLTX so you're saying there's a chance!
0 · Reply
Creisi
Creisi Apr. 4 at 4:32 PM
$MLTX Immediately after the sale was publicized; MLTX stock price GAINED 5.23%. It gained value after the sale which correlates to a large predatory entity accumulation. Shorts were also exiting positions, which is also an indicator of a large predatory entity swimming in the waters. I already covered this.
1 · Reply
Waitwhat
Waitwhat Apr. 4 at 4:03 PM
$MLTX Did the 3.75 million shares get completely sold then the stock dropped after it was revealed or did the stock drop as the shares were dumped on the market?
1 · Reply
LouKojak
LouKojak Apr. 4 at 3:36 PM
$MLTX one more reason for a buyout. Eli Lilly, Sanofi, and Merck have or are building small molecule drug manufacturing facilities in the US "Under Thursday’s executive order, companies that have signed a “most favoured nation” pricing deal and are actively building facilities in the US will have a zero-percent tariff." https://www.aljazeera.com/amp/news/2026/4/2/trump-unveils-100-percent-tariff-on-drugs-to-push-for-pharmaceutical-deals
3 · Reply
JTMinor1
JTMinor1 Apr. 4 at 3:26 PM
$MLTX I can imagine a huge bearish push down this week to shake the weak shares out. Huge build up of available short shares. Enjoy the ride, I’m holding.
1 · Reply